Schwab Charles Investment Management Inc. decreased its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 6.3% in the 3rd quarter, Holdings Channel reports. The firm owned 65,865 shares of the biotechnology company’s stock after selling 4,414 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Anika Therapeutics were worth $3,821,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ANIK. Rhumbline Advisers raised its stake in Anika Therapeutics by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 27,720 shares of the biotechnology company’s stock valued at $1,368,000 after purchasing an additional 96 shares during the last quarter. Legal & General Group Plc raised its stake in Anika Therapeutics by 10.6% in the 2nd quarter. Legal & General Group Plc now owns 26,636 shares of the biotechnology company’s stock valued at $1,314,000 after purchasing an additional 2,560 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in Anika Therapeutics by 3.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,315 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 126 shares during the last quarter. Federated Investors Inc. PA raised its stake in Anika Therapeutics by 4.0% in the 2nd quarter. Federated Investors Inc. PA now owns 9,376 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 363 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in Anika Therapeutics by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 4,060 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 608 shares during the last quarter. 84.91% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO Charles H. Sherwood sold 22,228 shares of the company’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $60.06, for a total transaction of $1,335,013.68. Following the completion of the transaction, the chief executive officer now owns 158,297 shares of the company’s stock, valued at approximately $9,507,317.82. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Richard Hague sold 5,250 shares of the company’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $54.48, for a total transaction of $286,020.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,762 shares of company stock valued at $2,178,445. Corporate insiders own 6.57% of the company’s stock.

Anika Therapeutics Inc. (NASDAQ:ANIK) opened at $56.64 on Friday. Anika Therapeutics Inc. has a one year low of $41.64 and a one year high of $60.29. The company has a market cap of $830.46, a PE ratio of 26.59, a PEG ratio of 3.43 and a beta of 1.44.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.46 EPS for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.05. Anika Therapeutics had a net margin of 28.23% and a return on equity of 13.40%. The company had revenue of $27.18 million during the quarter, compared to the consensus estimate of $27.44 million. During the same quarter in the prior year, the company posted $0.59 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. research analysts predict that Anika Therapeutics Inc. will post 1.9 earnings per share for the current year.

Several research analysts recently weighed in on ANIK shares. Barrington Research boosted their target price on shares of Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. BidaskClub downgraded shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/schwab-charles-investment-management-inc-has-3-82-million-position-in-anika-therapeutics-inc-anik/1806781.html.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.